Search Results - "Tumolo, S"

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV by Lévi, F.A., Boige, V., Hebbar, M., Smith, D., Lepère, C., Focan, C., Karaboué, A., Guimbaud, R., Carvalho, C., Tumolo, S., Innominato, P., Ajavon, Y., Truant, S., Castaing, D., De Baere, T., Kunstlinger, F., Bouchahda, M., Afshar, M., Rougier, P., Adam, R., Ducreux, M.

“…Systemic chemotherapy typically converts previously unresectable liver metastases (LM) from colorectal cancer to curative intent resection in ∼15% of patients…”
Get full text

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial by Garufi, C, Torsello, A, Tumolo, S, Ettorre, G M, Zeuli, M, Campanella, C, Vennarecci, G, Mottolese, M, Sperduti, I, Cognetti, F

“…Background: We assessed the effectiveness of cetuximab plus chronomodulated irinotecan, 5-fluorouracil (5-FU), leucovorin (FA) and oxaliplatin (L-OHP)…”
Get full text

Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis by Giacchetti, S., Dugué, P.A., Innominato, P.F., Bjarnason, G.A., Focan, C., Garufi, C., Tumolo, S., Coudert, B., Iacobelli, S., Smaaland, R., Tampellini, M., Adam, R., Moreau, T., Lévi, F.

“…Molecular circadian clocks can modify cancer chemotherapy effects, with a possible moderation according to sex differences. We investigated whether sex…”
Get full text

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

“…Previously, we have shown that the combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) and singleagent carboplatin produce similar survival and…”
Get full text

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification by Saracchini, S, Foltran, L, Tuccia, F, Bassini, A, Sulfaro, S, Micheli, E, Del Conte, A, Bertola, M, Gion, M, Lorenzon, M, Tumolo, S

“…Abstract Purpose of the study Trastuzumab combined with sequential chemotherapy with taxanes and anthracyclines as primary systemic therapy achieved high rates…”
Get full text

323 Vascular Endothelial Growth Factor as Prognostic Factor in Patients with Breast Cancer. a Multicentric Long-term Follow up Study by Lumachi, F, Santeufemia, D.A, Fadda, G.M, Lo Re, G, Tumolo, S, Miolo, G.M, Chiara, G.B, Basso, S.M.M

Get full text

343 Risk Factors of Breast Cancer Relapse. a Case-control Study and Results of Multivariate Analysis in a Cohort of 348 Patients Who Underwent Curative Surgery by Lumachi, F, Marino, F, Santeufemia, D.A, Lo Re, G, Tumolo, S, Chiara, G.B, Basso, S.M.M

Get full text

Salvage Treatment in Locoregional Recurrent Esophageal Carcinoma (EC) Using Intensity Modulated Radiation Therapy - Helical Tomotherapy (IMRT-HT) by Innocente, R, Santeufemia, D, Miolo, G, Gobitti, C, Trovò, M.G, Tumolo, S, Bidoli, E, Baresic, T, Boz, G, De Paoli, A

Get full text

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer by Piccart, M J, Bertelsen, K, Stuart, G, Cassidy, J, Mangioni, C, Simonsen, E, James, K, Kaye, S, Vergote, I, Blom, R, Grimshaw, R, Atkinson, R, Swenerton, K, Trope, C, Nardi, M, Kaern, J, Tumolo, S, Timmers, P, Roy, J-A, Lhoas, F, Lidvall, B, Bacon, M, Birt, A, Andersen, J, Zee, B, Paul, J, Pecorelli, S, Baron, B, McGuire, W

“…Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have…”
Get more information

Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases by Santeufemia, D A, Capobianco, G, Re, G Lo, Miolo, G M, Fadda, G M, Cherchi, P L, Tumolo, S

“…Vulvar cancer (VC) is a rare disease, usually diagnosed in a stage still amenable to potentially curative treatments, including surgery and/or radiation…”
Get more information

Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma by Lissoni, A., Gabriele, A., Gorga, G., Tumolo, S., Landoni, F., Mangioni, C., Sessa, C.

“…Purpose to evaluate the toxic effects and antitumour activity of a multidrug regimen with cisplatin, epirubicin and paclitaxel (CEP) as initial therapy in…”
Get full text

Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group by van Wijk, F.H, Lhommé, C, Bolis, G, Scotto di Palumbo, V, Tumolo, S, Nooij, M, de Oliveira, C.F, Vermorken, J.B

“…The aim of this study was to investigate the efficacy and toxicity of carboplatin given as monotherapy in endometrial adenocarcinoma. Cisplatin is one of the…”
Get full text

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study by CONTE, P. F, DONATI, S, NACCARATO, A. G, ESPOSTI, R. Degli, BONARDI, S, BOTTINI, A, SARACCHINI, S, TUMOLO, S, GULLO, G, SANTORO, A, CRINO, L, GENNARI, A, GUARNERI, V, ORLANDINI, C, RONDINI, M, RONCELLA, M, MARINI, L, COLLECCHI, P, VIACAVA, P

“…This trial was conducted to assess the activity and tolerability of the gemcitabine, epirubicin, taxol triplet combination in patients with operable breast…”
Get full text

Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer by Nicoletto, M O, Tumolo, S, Sorio, R, Cima, G, Endrizzi, L, Nascimben, O, Vinante, O, Artioli, G, Donach, M, Cartei, G

“…The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July…”
Get more information

Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study by Frustaci, S, Buonadonna, A, Galligioni, E, Favaro, D, De Paoli, A, Lo Re, G, Sorio, R, Tumolo, S, Monfardini, S

“…To determine the maximum-tolerated dose (MTD) of 4'-epidoxorubicin (EPI) in combination with full dose of ifosfamide (IFO) when granulocyte-macrophage…”
Get more information

Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group Study by Nicoletto, M O, Tumolo, S, Talamini, R, Salvagno, L, Franceschi, S, Visonà, E, Marin, G, Angelini, F, Brigato, G, Scarabelli, C, Carbone, A, Cecchetto, A, Prosperi, A, Rosabian, A, Giusto, M, Cima, G P, Morassut, S, Nascimben, O, Vinante, O, Fiorentino, M V

“…The usefulness of extensive and repetitive surgery for patients with ovarian cancer still remains unproven (at least for some conditions). We planned an…”
Get more information

6086 Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial) by Garufi, C, Torsello, A, Tumolo, S, Mottolese, M, Melucci, E, Campanella, C, Zeuli, M, Sperduti, I, Ettorre, G.M, Cognetti, F

Get full text

A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group by Di Bartolomeo, M, Bajetta, E, Bochicchio, A M, Carnaghi, C, Somma, L, Mazzaferro, V, Visini, M, Gebbia, V, Tumolo, S, Ballatore, P

“…Previous experiences in the treatment of neuroendocrine tumours have demonstrated some activity of single agents such as adriamycin, fluorouracil (FU),…”
Get more information

Hepatic Intra-Arterial Chemotherapy (HIAC) of High Dose Mitomycin and Epirubicin Combined with Caval Chemofiltration Versus Prolonged Low Doses in Liver Metastases from Colorectal Cancer: a Prospective Randomized Clinical Study by Fiorentini, G., Poddie, D.B., Cantore, M., Rossi, S., Tumolo, S., Dentico, P., Bernardeschi, P., Guadagni, S., Rossi, G., Valori, V.M., De Simone, M.

“…A multicenter randomized study comparing high dose of mitomycin and epirubicin given as hepatic intra-arterial chemotherapy (HIAC) combined with caval…”
Get full text

Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group by Pawinski, A., Tumolo, S., Hoesel, G., Cervantes, A., van Oosterom, A.T., Hoctin Boes, G., Pecorelli, S.

“…Currently, available chemotherapy regimens for patients with advanced or recurrent endometrial cancer are generally not curative. Thus, there is a need to…”
Get full text